share_log

Catalyst Pharmaceuticals (NASDAQ:CPRX) Increases 5.4% This Week, Taking Five-year Gains to 520%

Catalyst Pharmaceuticals (NASDAQ:CPRX) Increases 5.4% This Week, Taking Five-year Gains to 520%

催化剂制药(纳斯达克股票代码:CPRX)本周上涨5.4%,使五年涨幅达到520%
Simply Wall St ·  2023/12/03 08:33

Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly amazing gains over the years. To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 520% over five years. This just goes to show the value creation that some businesses can achieve. And in the last month, the share price has gained 13%. But this could be related to good market conditions -- stocks in its market are up 5.5% in the last month. We love happy stories like this one. The company should be really proud of that performance!

当你购买并持有真正优秀的企业时,长期投资可能会改变生活。这些年来,我们已经看到了一些非常惊人的成就。换句话说,催化剂制药公司(纳斯达克股票代码:CPRX)的股价在五年内飙升了520%。这只是表明某些企业可以实现的价值创造。而在上个月,股价上涨了13%。但这可能与良好的市场状况有关——其市场上的股票在上个月上涨了5.5%。我们喜欢这样的快乐故事。公司应该为这种表现感到非常自豪!

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

在连续7天表现稳健的背景下,让我们来看看公司的基本面在推动长期股东回报方面发挥了什么作用。

View our latest analysis for Catalyst Pharmaceuticals

查看我们对 Catalyst 制药的最新分析

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

在他的文章中 格雷厄姆和多兹维尔的超级投资者 沃伦·巴菲特描述了股价如何并不总是合理地反映企业的价值。考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。

During the five years of share price growth, Catalyst Pharmaceuticals moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

在股价增长的五年中,Catalyst Pharmicals从亏损转为盈利。正如我们在这里看到的那样,这种转变可能是一个转折点,可以证明股价的强劲上涨是合理的。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下图描述了 EPS 随着时间的推移是如何变化的(点击图片可以看到确切的值)。

earnings-per-share-growth
NasdaqCM:CPRX Earnings Per Share Growth December 3rd 2023
纳斯达克CM:CPRX 每股收益增长 2023 年 12 月 3 日

It might be well worthwhile taking a look at our free report on Catalyst Pharmaceuticals' earnings, revenue and cash flow.

我们关于催化剂制药公司收益、收入和现金流的免费报告可能值得一看。

A Different Perspective

不同的视角

Investors in Catalyst Pharmaceuticals had a tough year, with a total loss of 14%, against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 44% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Catalyst Pharmaceuticals (1 shouldn't be ignored) that you should be aware of.

Catalyst Pharmicals的投资者度过了艰难的一年,总亏损了14%,而市场涨幅约为14%。但是,请记住,即使是最好的股票有时也会在十二个月内表现逊于市场。好的一面是,长期股东已经赚了钱,在过去的五年中,每年增长44%。最近的抛售可能是一个机会,因此可能值得查看基本面数据以寻找长期增长趋势的迹象。尽管值得考虑市场状况可能对股价产生的不同影响,但还有其他因素更为重要。例如,我们已经确定了 Catalyst Pharmicals 的 3 个警告信号(1 个不容忽视),你应该注意这些信号。

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发